MetaVia (MTVA)
NASDAQ:MTVA
Want to see MTVA full AI Analyst Report?
MTVA Stock Chart & Stats
$1.40
-$0.13(-5.60%)
At close: 4:00 PM EST
$1.40
-$0.13(-5.60%)
Day’s Range― - ―
52-Week Range$0.97 - $19.02
Previous CloseN/A
Volume36.62K
Average Volume (3M)3.42M
Market Cap
$19.88M
Enterprise Value-$5.06M
Total Cash (Recent Filing)$13.73M
Total Debt (Recent Filing)$194.00K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 18, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.03
Shares Outstanding5,164,370
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit337.43
Enterprise Value/Ebitda0.37
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development And Dosing StrategyIRB approval to advance into the next stage and plans to test dose-escalation and simplified titration strategies may refine dosing to enhance effectiveness and patient tolerability, potentially improving competitiveness in the obesity market.
Clinical Efficacy And TolerabilityEarly clinical results showed rapid and meaningful reductions in body weight and waist size with manageable gastrointestinal side effects and no treatment-related discontinuations, suggesting strong efficacy with a favorable tolerability profile.
Mechanism Of ActionAnalyst highlights that the lead drug's dual-action oxyntomodulin analogue both suppresses appetite and boosts energy expenditure, offering a differentiated approach that could deliver greater fat loss than existing therapies.
Bears Say
Analyst Price Target ImpactAnalyst's price target was lowered following the share increase, which may weigh on investor sentiment and limit near-term upside.
Liquidity And Financing RiskThe company faces ongoing operating losses and limited cash, increasing dependence on additional financing and elevating financial risk for investors.
Share Dilution And Valuation PressureA recent public offering enlarged the share count, diluting existing holdings and placing downward pressure on per-share valuation assumptions.
MetaVia News
MTVA FAQ
What was MetaVia’s price range in the past 12 months?
MetaVia lowest stock price was $0.97 and its highest was $19.02 in the past 12 months.
What is MetaVia’s market cap?
MetaVia’s market cap is $19.88M.
When is MetaVia’s upcoming earnings report date?
MetaVia’s upcoming earnings report date is Aug 18, 2026 which is in 84 days.
How were MetaVia’s earnings last quarter?
MetaVia released its earnings results on May 14, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.743 by -$0.047.
Is MetaVia overvalued?
According to Wall Street analysts MetaVia’s price is currently Undervalued.
Does MetaVia pay dividends?
MetaVia does not currently pay dividends.
What is MetaVia’s EPS estimate?
MetaVia’s EPS estimate is -0.82.
How many shares outstanding does MetaVia have?
MetaVia has 5,164,370 shares outstanding.
What happened to MetaVia’s price movement after its last earnings report?
MetaVia reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.743. Following the earnings report the stock price went down -6.723%.
Which hedge fund is a major shareholder of MetaVia?
Currently, no hedge funds are holding shares in MTVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MetaVia
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$14.00
▲(900.00% Upside)
Technical Analysis
Ownership Overview
6.32% Insiders
0.45% Mutual Funds
0.19% Other Institutional Investors
93.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---